Various media have reported on studies addressing COVID-19 to be undertaken by several research centres in Catalonia. Among the groups involved is IRB Barcelona’s Structural Bioinformatics and Network Biology Lab, headed by Patrick Aloy. IRB Barcelona is one of eight research centres chosen by the European Commission to study new approaches to treat and diagnose COVID-19 and thus halt the spread of the virus.
Furthermore, NostrumBiodiscovery, cofounded by IRB Barcelona researcher Modesto Orozco, is collaborating with the Barcelona Supercomputing Center–Centro Nacional de Supercomputación (BSC-CNS) in another EC project. In this regard, the project aims to use cutting-edge biocomputation to support the intelligent design of drugs to treat COVID-19.
Link to: eldiario.es
Link to: El Confidencial
Link to: EFE
Link to: La Vanguardia
Link to: 20minutos
About IRB Barcelona
The Institute for Research in Biomedicine (IRB Barcelona) pursues a society free of disease. To this end, it conducts multidisciplinary research of excellence to offer pioneering solutions to unresolved medical needs in cancer and other diseases related to ageing. It establishes technology transfer agreements with the pharmaceutical industry and major hospitals to bring research results closer to society and organises a range of science outreach activities to engage the public in an open dialogue. IRB Barcelona is an international centre that hosts 400 employees and more than 30 nationalities. Recognised as a Severo Ochoa Centre of Excellence since 2011, IRB Barcelona is a CERCA centre and member of the Barcelona Institute of Science and Technology (BIST).